Latest news and press releases about Pfizer Inc. (PFE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
Price
| Price | $27.41 |
| Market Cap | $156.2B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 36.73 |
| Price / Book | 1.86 |
| EV / EBITDA | 13.76 |
| Dividend Yield | 6.19% |
Profitability
| Return on Equity | 8.99% |
| Return on Invested Capital | 8.84% |
| Return on Assets | 3.73% |
| Gross Margin | 71.32% |
| Operating Margin | 25.08% |
| Net Margin | 6.81% |
Related companies: AMGN · BMY · BSX · DHR · GILD · GSK · MRK
Explore sector: Healthcare · Drug Manufacturers - General
More sections of PFE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks